A biopharmaceutical company that focuses on developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, announced that the U.S. Food and Drug Administration (FDA) has granted approval of "Eravacycline" for the treatment of complicated intra-abdominal infections (cIAI). In clinical trials, Eravacycline was well-tolerated and achieved high clinical cure rates in patients with cIAI, demonstrating statistical non-inferiority to two widely used comparators – ertapenem and meropenem.
Eravacycline is indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. To reduce the development of drug-resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, Eravacycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible…
